The in vivo targeting effect of rapamycin can eliminate TSC2-null xenograft tumor model growth, induce apoptosis, increase the survival rate of tumor-bearing mice, and prevent tumor regeneration after treatment16. The gene discussed is TSC2; the disease is neoplasm.